Adherium Ltd.
- -
AUD
- -
- -
ISIN
AU0000470916
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- John Perry
- Full Time Employees
- 40
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 447 Collins Street Melbourne VIC Australia 3000
- IPO Date
- Aug 26, 2015
- Website
- adherium.com
- Similar Companies
- Business
- Adherium Limited is a digital health company specializing in the development, manufacture, and supply of respiratory eHealth technologies that enhance patient medication adherence, remote monitoring, and data management for chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its core products include the Hailie Smartinhaler system, which comprises Bluetooth-enabled sensors that attach to inhalers to provide real-time usage feedback; the Hailie app for patient engagement; and the Hailie portal and remote patient management platform designed for healthcare providers and payers to monitor patient data remotely. Adherium's sensor technology uniquely includes physiological parameters, such as respiratory flow data, and is cleared for market use in the US, Australia, and the UK. The company operates internationally with primary revenue generated in Europe, and geographic segments including New Zealand, Australia, Europe, North America, and Asia. Founded in 2001, Adherium is headquartered in Melbourne, Australia. Recent major developments include the production and market release of next-generation Hailie sensors compatible with leading inhaler brands such as GlaxoSmithKline's Ventolin, Advair/Flixotide, and Flovent/Seretide, expanding its sensor portfolio with enhanced physiological measurement capabilities. In 2023, Adherium entered a strategic partnership with US-based SENTA Partners to roll out the Hailie platform across clinics in Georgia, USA, focusing on improved adherence and inhaler technique, supported by building a dedicated US-based implementation team. Additionally, the company announced new partnerships and contract signings with healthcare providers and pharmacy benefit management organizations to scale its US operations and broaden patient enrollment and reimbursement activities. Adherium also continues to invest in product innovation and R&D, aiming to enhance its digital health offerings within the respiratory medical devices and eHealth sectors. Adherium maintains a strong focus on chronic respiratory care markets, targeting patients, healthcare providers, payers, and pharmaceutical partners with its integrated digital health solutions. The company emphasizes leveraging its Hailie platform to deliver improved health outcomes, reduce healthcare costs, and enable remote patient management under established reimbursement codes, supporting long-term disease management and adherence monitoring. Adherium is listed on the Australian Securities Exchange (ticker: ADR.AX). This comprehensive corporate profile reflects Adherium Limited's business activities, key products, geographic presence, and significant recent strategic changes as of late 2025.